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Summary
Objective: Cartilage oligomeric matrix protein (COMP) mutations have been identified as responsible for two arthritic disorders, multiple
epiphyseal dysplasia (MED) and pseudoachondroplasia (PSACH). However, the function of COMP in chondrogenic differentiation is largely
unknown. Our investigation focuses on analyzing the function of normal COMP protein in cartilage biology.
Methods and results: To explore the function of COMP we make use of an in vitro model system for chondrogenesis, consisting of murine
C3H10T1/2 mesenchymal cells maintained as a high-density micromass culture and stimulated with bone morphogenetic protein 2 (BMP-2).
Under these culture conditions, C3H10T1/2 cells undergo active chondrogenesis in a manner analogous to that of embryonic limb
mesenchymal cells, and have been shown to serve as a valid model system to investigate the mechanisms regulating mesenchymal
chondrogenesis. Our results indicate that ectopic COMP expression enhances several early aspects of chondrogenesis induced by BMP-2
in this system, indicating that COMP functions in part to positively regulate chondrogenesis. Additionally, COMP has inhibitory effects on
proliferation of cells in monolayer. However, at later times in micromass culture, ectopic COMP expression in the presence of BMP-2 causes
an increase in apoptosis, with an accompanying reduction in cell numbers in the micromass culture. However, the remaining cells retain their
chondrogenic phenotype.
Conclusions: These data suggest that COMP and BMP-2 signaling converge to regulate the fate of these cells in vitro by affecting both early
and late stages of chondrogenesis.
© 2003 Published by Elsevier Science Ltd on behalf of OsteoArthritis Research Society International.
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Introduction
Cartilage oligomeric matrix protein (COMP) is a 524 kDa
oligomeric glycoprotein1,2. It is a member of the thrombo-
spondin gene family2,3 and has recently been termed
thrombospondin 5. The mature protein is a pentamer of
identical subunits that interact at their N-terminus through
disulfide linkages, forming a bouquet-like structure1,4,5. The
pentamer is formed from an alpha-helical coiled coil struc-
ture located at the amino terminus of each monomer3,4,6.
COMP contains both epidermal growth factor-like repeats
and calcium-binding repeats located in the central region
of the protein3. These repeats are contained in all the
thrombospondins3.
COMP was originally identified as a component of carti-
lage and has been found to be highly expressed in both
developing and mature cartilage as well as in tendon and
ligament1,7–9. During fetal development, COMP expression
was pronounced in the territorial matrix around the
chondrocytes of the growth plate8. However, in adult carti-
lage, COMP has been shown to be located primarily in the
interterritorial matrix8. Since COMP is localized to the
territorial matrix of the chondrocytes, it has been proposed
that it may directly interact with cells, which has been
recently shown to be the case10. But whether COMP plays
a direct role in the control of chondrocyte proliferation and
differentiation is not yet known.
While the function of COMP in cartilage is not yet known,
mutations in the COMP gene have been identified that are
responsible for at least two forms of heritable osteoarthritis
(OA), multiple epiphyseal dysplasia (MED or EDM1) and
pseudoachondroplasia (PSACH)11,12. Although it is not
currently known if the onset of OA is secondary to poor
joint formation or if it is a primary result of the action of the
mutated COMP protein, it is known that many of the
mutations in COMP reside in the calcium-binding
region11,12. It now appears that these mutant COMP mol-
ecules are indeed defective in binding calcium10. Since the
initial identification of COMP as the causative agent in MED
and PSACH, a large number of mutations have been
identified in the COMP gene in these patients13–19. These
findings have led to the postulate that certain features of
heritable as well as sporadic OA may have roots in the
noncollagenous components of cartilage such as COMP.
This, however, remains to be determined.
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While it is likely that COMP plays an important role in
cartilage biology, the nature of this role is unknown. To
better understand the normal function of COMP in cartilage
biology, we have utilized an in vitro mesenchymal chondro-
genesis model system, consisting of the pluripotential
murine mesenchymal cell line (i.e. C3H10T1/2 cells).
These cells are able to undergo chondrogenesis in micro-
mass culture following treatment with bone morphogenetic
protein-2 (BMP-2)20–23. We report here that ectopic ex-
pression of COMP in these cells by retroviral gene
transfer induces a number of effects on BMP-2-mediated
chondrogenesis in this system.
Methods
CELL CULTURE, TRANSFECTIONS, INFECTIONS AND BMP-2
TREATMENT
C3H10T1/2 mesenchymal fibroblasts and ecotropic
Phoenix packaging cells were obtained from ATCC and
monolayer cultures were maintained in DMEM supple-
mented with 10% fetal bovine serum (FCS, Atlanta Biologi-
cals), 50 U/ml penicillin and 50 mg/ml streptomycin. The
cultures were incubated in a humidified atmosphere at
37°C and 5% CO2. The medium was changed every 3
days. All transfection experiments were initiated on 50%
confluent monolayer cultures. Plasmids (30 µg) were trans-
fected by the calcium phosphate procedure. The human
COMP cDNA was cloned into the Eco R1 site of the pBABE
retroviral vector. When transfected into Phoenix cells this
plasmid is converted to infectious retrovirus. Following the
transfection of the pBABE constructs, the Phoenix cells
were placed in a 32°C humidified incubator for 48 h, since
the virus is more stable at 32°C. The medium containing
infectious virus was harvested and filtered through a
0.2 µm filter to eliminate any contaminating cells. The virus
was then used to infect subconfluent, proliferating
C3H10T1/2 fibroblasts in the presence of 4 µg/ml of Poly-
brene (Sigma).
The micromass culture technique was modified from the
work of Ahrens et al.24 as in Denker et al.25. Cells were
trypsinized and resuspended in Hams F12 medium with
10% FCS at a concentration of 107 cells/ml. A 10 µl drop of
this cell suspension was placed in either a 10 cm poly-
styrene tissue culture plate (Corning) or the center of a well
of a 24-well polystyrene tissue culture dish (Corning). The
cells were allowed to adhere for 2 h at 37°C and then
medium containing 10% FCS, with or without added BMP-2
(100 ng/ml, a generous gift from the Genetics Institute, Inc.,
Cambridge, MA, USA), as indicated subsequently. The
media were changed every 3 days.
HISTOLOGY, METABOLIC SULFATE LABELING AND FLOW
CYTOMETRY
To measure the production of sulfated glycosamino-
glycans, compared with total protein, sodium 35SO4 and
3H-leucine (NEN, Boston, MA), were added to the medium
at final specific activities of 5 and 1 µCi/ml, respectively, at
the times indicated below. After incubation for an additional
24 h, the medium was removed and cells were rinsed
extensively with PBS, and fixed in 4% paraformaldehyde.
Radioactive incorporation of 35SO4 and 3H-leucine was
assessed by liquid scintillation counting.
Whole-mount cultures were rinsed twice with phosphate
buffered saline (PBS), fixed for 20 min in 4% paraformalde-
hyde and then as indicated below, stained with a 1%
solution of Alcian Blue 8-GX (Sigma, St. Louis, MO) at pH
1. Sections were immunostained for collagen type II using
monoclonal antibody CIIC1 as described previously20. Fol-
lowing deparaffinization and rehydration, sections were
digested with 0.5 mg/ml bovine testicular hyaluronidase in
10 mM NaH2PO4/KH2PO4, at pH 6 in the presence of
6-aminocaproic acid, 1 mM phenylmethylsulfonlyl fluoride
(PMSF) and 5 mM benazamidine hydrochloride overnight,
then swelled in 0.5 M acetic acid for 5 h. Incubations with
primary antibody (42 µg/ml in 10% goat serum in PBS) for
60 min at 37°C were followed by rinsing with PBS and
incubation for 20 min with biotin-conjugated broad-
spectrum anti-IgG secondary antibody. Visualization was
performed using streptavidin-conjugated horseradish
peroxidase Histostain-SP Kit (Zymed Laboratories) and
ImmunoPure Metal Enhanced DAB Substrate Kit (Pierce,
Rockford, IL).
For cell cycle analysis (flow cytometry), cells were rinsed
once in chilled PBS then trypsinized and resuspended in
10 ml DMEM plus 10% FCS. The cells were pelleted and
resuspended in 70% ethanol. The cells were kept on ice for
10 min, pelleted and then treated with RNAase A (180 µg,
Sigma) for 30 min at room temperature. Propidium iodide
(Sigma) was added to a final concentration of 75 µg/ml.
Cell cycle analysis was performed on a Coulter Profile 2,
Flow Cytometer.
RNA ISOLATION, NORTHERN AND RT-PCR ANALYSIS
Total RNA was isolated from cells by the Trizol method
(Gibco-BRL). Oligo dT was used as the primer in the
reverse transcription reaction which was followed by a PCR
reaction with the appropriate primers. For the RT-PCR
reactions, 1 µg of total RNA from the cells was used in each
reaction. All total RNA samples were DNase I treated in the
RT reaction prior to the PCR reactions. Additionally, as a
control, PCR done in the absence of RT was negative for
any ethidium bromide stained bands (data not shown).
PROTEIN ANALYSIS AND IMMUNOBLOTTING
Cells were cultured in serum-free medium for 6–8 h. The
medium was harvested and the cellular debris was re-
moved by centrifugation. Aliquots of the medium were
added to two volumes of ice-cold acetone and the proteins
were precipitated at −20°C, as in Jordan-Sciutto et al.26.
The protein precipitate was pelleted by centrifugation at
14,000×g for 10 min at 4°C. The protein precipitate was
then boiled in SDS-PAGE sample buffer in the presence of
reducing agent (DTT). For immunoblotting, the proteins
were electrophoretically resolved by SDS-PAGE (40 µg
protein/lane) and transferred onto nitrocellulose filters. The
blots were then washed in TBST buffer (10 mM Tris, pH 8;
150 mM NaCl; 0.05% Tween 20), blocked with 2.5% bovine
serum albumin (BSA) in TBST for 30 min at room tempera-
ture, and incubated with the primary antibodies for 60 min
at room temperature in TBST. Anti-human COMP antibody
(a kind gift of Dr Heinegard) was used at a concentration of
1:500. The blot was then washed three times, 10 min each,
in TBST, then incubated with a 1:7500 dilution of secondary
antibody conjugated to alkaline phosphatase, for 30 min at
room temperature in TBST. The blot was then processed
using the Protoblot system (Promega).
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IN SITU HYBRIDIZATION
Embryonic mice (16.5 dpc) were fixed, embedded and
sagittally sectioned, as in Wawersik and Epstein27. The
sections (8 µM) on glass slides were then processed for in
situ hybridization using a 35S-labeled mouse COMP probe.
The probe (either antisense or sense riboprobe) was gen-
erated with a fragment of the mouse COMP cDNA span-
ning nucleotide residues 1409–2051 (642 bp). The sections
were hybridized (1×106 cpm total) to probe (55°C), washed,
RNase treated, immersed in photographic emulsion and
then processed for autoradiography at Day 10. The auto-
radiographs of the probed sections were photographed
under darkfield optics where a positive hybridization signal
is evident as white grains. Additionally, near adjacent
sections were stained for histology using Mallory’s
Trichrome. As controls, the radiolabeled sense probe
showed no detectable hybridization (data not shown).
Results
EXPRESSION OF COMP DURING MOUSE EMBRYOGENESIS IN
DEVELOPING CARTILAGE
Using the cloned murine COMP cDNA28, we localized
COMP expression in the mouse embryo undergoing ac-
tive chondrogenesis and cartilage development at Day
16.5 pc. As shown in Fig. 1, a high-level expression of
COMP was seen at multiple sites in the footpad, trunk
and tail and in particular, regions very active in cartilage
formation. These included the developing digits in the
Fig. 1. In situ hybridization demonstrates widespread COMP expression in the developing cartilage of Day 16.5 embryonic mouse. Sagittal
sections of embryonic mice (day 16.5 post coitus dpc) were processed for in situ hybridization for COMP mRNA, as described in the Methods
section. The sections were observed by darkfield optics to visualize the in situ hybridization signal (left column), or by bright field optics to
view the histology by Mallory’s Trichrome stain (right column). Three regions of the embryo are shown: (A,B) footpad, (C,D) tail vertebrae and
(E,F) trunk. Positive hybridization signals (white grains indicated by the arrows) were localized to sites of active chondrogenesis in the
developing skeletal elements of the digits of the paw (A), the tail (C) and the vertebral column and sternum (E). The data show that COMP
expression is extensive in the regions undergoing chondrogenesis. The black arrows (B, D and F) indicate the corresponding regions in the
control, stained sections. Controls using radiolabeled sense probe showed no detectable hybridization signal (data not shown).
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footpad, the tail vertebrae, and spine, ribs and sternum
all corresponding to sites involved in endochondral ossifi-
cation. This tissue distribution clearly indicates that
COMP expression is part of the cartilage development
program.
INDUCTION OF CHONDROGENESIS IN VITRO BY BMP-2 USING
C3H10T1/2 CELLS
Since COMP is expressed to high levels during embry-
onic development, it has therefore been assumed that
COMP plays some role in cartilage development. However
to date, this role is not known. To examine the role of
COMP during chondrogenesis, an in vitro culture system,
of C3H10T1/2 mouse mesenchymal cells was therefore
used in the studies described here. These multipotential
cells are able to differentiate in culture along multiple
pathways depending on the stimulus29. For example, they
are capable of differentiating into myoblasts, osteoblasts,
adipocytes or chondrocytes under the appropriate culture
conditions20–25,29–32. Importantly, it has been shown that
these C3H10T1/2 cells can preferentially undergo chondro-
genesis when cultured in a high-density micromass en-
vironment in the presence of BMP-220,21,25. This culture
system presents a useful model to study COMP function,
since the effect of misexpression of COMP on chondro-
genesis can therefore be analyzed in vitro.
An example of the chondrogenic differentiation of these
C3H10T1/2 cells is shown in Fig. 2A, where the cells
spotted in a micromass (107 cells/ml in a 10 µl drop) and
treated with BMP-2 show prominent positive staining with
Alcian Blue by Days 7–10 in culture. This positive staining
indicates the presence of highly negatively charged sul-
fated proteoglycans of cartilage matrix33, which is accom-
panied by a corresponding increase in metabolic 35SO4
incorporation into sulfated proteoglycans [Fig. 2(B)]. RT-
PCR analysis shows that there is a clear increase in the
level of type II collagen (both the ‘A’ and the ‘B’ splicing
isoforms) [Fig. 2(C)]. The increase in the IIB isoform
indicates the presence of differentiated cartilage34,35.
These chondrogenic markers are not seen in monolayer
cultures of these cells treated with BMP-2 (references
20,21,25 and data not shown). When the micromass cul-
tures were sectioned and examined by immunohistochem-
istry, collagen type II was detected in the sections, as
shown in Fig. 2D. The intensity of the staining in the BMP-2
stimulated cultures was considerably higher than the con-
trol cultures, indicating an abundance of matrix [Fig. 2(D)].
In this regard, we have also previously shown significant
increases in the level of cartilage proteoglycan link protein
in the BMP-2-treated micromass cultures, compared with
the untreated cultures20.
RETROVIRAL GENE TRANSFER OF COMP IN CULTURES OF
C3H10T1/2 CELLS
To determine the effect of COMP on chondrogenesis, we
ectopically expressed COMP in C3H10T1/2 cells and then
Fig. 2. BMP-2 treatment of micromass cultures of C3H10T1/2 cells
leads to induction of chondrogenesis. C3H10T1/2 cells were
cultured in a micromass environment in the presence or absence
of 100 ng/ml of BMP-2, as described in the Methods section. (A)
Alcian Blue stain. Alcian Blue staining of paraformaldehyde fixed,
Day 5 cultures reveals a significant level of chondrogenesis in the
BMP-2-treated micromasses. (B) Metabolic sulfate incorporation.
35SO4 was added to the micromass cultures (5 µCi/ml final con-
centration) for a 24 h period ending at Day 5 or 7. 3H-leucine at
1 µCi/ml (final concentration) was also added as a control to
standardize for differences in protein levels. At the end of the
labeling period, the cultures were washed extensively in PBS to
remove any unincorporated label and then fixed in 4% paraformal-
dehyde. The amount of radioactive incorporation in each micro-
mass was determined by scintillation counting. The ratio of 35SO4
to 3H-leucine incorporation on Days 5 and 7 is shown. The data
show higher sulfate incorporation in the BMP-2-treated cultures
(slashed bars) compared with controls (solid). (C) RT-PCR analy-
sis. Total RNA isolated on Day 5 of culture was processed for
RT-PCR using primers specific for mouse collagen type II and
mouse β-actin. The primers for type II collagen differentiate be-
tween the ‘A’ and ‘B’ forms of the transcript (the ‘B’ form is cartilage
specific). The reaction products, as shown, were electrophoresed
on an agarose gel, which was stained with ethidium bromide. The
stained gel shows a higher level of expression of both collagen
type II transcripts in the BMP-2-treated cultures relative to the
levels of β-actin mRNA. (D) Immunohistochemistry. Day 7 micro-
mass cultures were processed for immunohistochemistry of colla-
gen type II and revealed a significant level of this cartilage matrix
protein in the BMP-2-treated cultures, compared with untreated
controls. Collagen type II is detected by HRP staining (shown as
red), and the cells were counterstained with hematoxylin (blue).
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assessed its effect on chondrogenesis, following micro-
mass culture of these cells. We first determined the level of
endogenous COMP expression in these cells, prior to any
ectopic expression of COMP. C3H10T1/2 cells were found
to express no detectable COMP, either by Northern blot
analysis or by RT-PCR (using primers specific for the
mouse COMP sequence; reference 28). These cells there-
fore represent an excellent cell line to test the effects of
ectopic COMP expression since they are effectively null for
COMP expression. The human COMP cDNA was then
cloned into the pBABE retroviral vector, which produces a
replication defective virus, which was then transfected into
the Phoenix ecotropic packaging cell line. As a control, the
retroviral plasmid alone was separately transfected into the
Phoenix cells. The medium containing the infectious virus
was harvested, filtered and used to infect subconfluent
(20%), proliferating C3H10T1/2 mesenchymal fibroblasts,
in the presence of Polybrene to enhance the infection. The
cells were then grown to confluence for an additional 72 h.
Under these conditions, the infection level is approximately
90–95%, based on X-gal staining of β-galactosidase
activity produced by expression of LacZ in the pBABE
retroviral vector control (data not shown).
Following outgrowth of the infected cells, they were first
monitored for expression of COMP. As shown in the RT-
PCR analysis in Fig. 3A, COMP is expressed at a high level
in the cells infected with pBABE-COMP retrovirus as op-
posed to the control-infected culture. Immunoblot analysis
of secreted proteins from the cells grown in serum-free
medium showed expression of COMP protein [Fig. 3(B)].
As shown in Fig. 3B, the asterisk denotes a protein de-
tected by the secondary antibody, whose levels appear to
be elevated in the COMP expressing cells. One possibility
for the elevated levels is that COMP may positively affect
secretion of other proteins from the cell. In this regard we
do see some elevation in other high-molecular proteins in
COMP-infected cells (Hall, unpublished observations).
Taken together, these data indicate that the retroviral
transfer of COMP results in a detectable level of ectopic
expression. Since mutant COMP expression is known to
lead to an altered cellular morphology, and in particular an
enlarged and distended endoplasmic reticulum36–38, it was
important to determine if this altered morphological pheno-
type was present in the COMP expressing cells. As seen in
Fig. 3C, the COMP expressing cells are morphologically
Fig. 3. Ectopic expression of COMP by retroviral gene transfer in
cultures of C3H10T1/2 mesenchymal cells. (A) RNA analysis.
RT-PCR was performed on 1 µg of total RNA isolated from
confluent monolayer cultures of murine C3H10T1/2 cells at 7 days
postinfection with either the control (pBABE) or the COMP ex-
pressing (pBABE-COMP) retrovirus. Also included was RNA from
uninfected control C3H10T1/2 cells. The RT-PCR reaction was
performed with primers specific for either COMP or β-actin and the
reaction products were electrophoresed on an agarose gel,
stained with ethidium bromide. The bands corresponding to COMP
and β-actin are indicated and show a significant level of ectopic
COMP expression in the pBABE-COMP infected culture but no
detectable expression in the control. (B) Immunoblot analysis. The
cells at 7 days postinfection with either the control or COMP
retrovirus, as in (A), were cultured in serum-free media for 12 h.
The media were harvested, the protein precipitated in cold ac-
etone, which were analyzed by SDS-PAGE in the presence of
reducing agent (DTT). The SDS-PAGE gel was immunoblotted and
the blot incubated with an antibody generated against human
COMP (the secondary antibody was conjugated to alkaline phos-
phatase). (Left side) The band corresponding to the COMP mono-
mer protein is evident only in the extracts of the pBABE-COMP
infected cells. (Right side) An identical immunoblot was incubated
with secondary antibody only. The asterisk denotes a protein
detected by the secondary antibody. (C) Phase contrast micros-
copy. Monolayer cells infected with control and COMP retrovirus (7
days postinfection), as in (A), were photographed by phase con-
trast microscopy. The cells infected with each retrovirus are
indicated. The results revealed no significant differences in the
phenotype between the control and COMP expressing cells.
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identical to the control cells. This indicates that COMP
expression does not adversely affect cell structure or
morphology (i.e. no obvious increase in cell size or number
of subcellular vesicles are evident in the COMP expressing
cells).
ECTOPIC COMP EXPRESSION AFFECTS CELL GROWTH AND
CHONDROGENESIS IN VITRO
To determine the functional consequences of this ectopic
expression, the cells infected with either the control virus or
the COMP expressing virus were cultured in a monolayer.
Since COMP protein is present in the territorial zone of
proliferative chondrocytes in the growth plate during devel-
opment7, it is possible that COMP functions in part to
regulate the extent of chondrocyte proliferation. To assess
the growth regulatory function of COMP in culture, the
cultures were seeded at equal cell density and processed
for viable cell counts and flow cytometry at daily intervals
thereafter. As seen in Fig. 4A, the cells expressing COMP
had a demonstrable slow growth phenotype, evident as a
twofold decrease in cell number by Day 4 of culture. This
reduction in the level of cell proliferation was mirrored by a
twofold decrease in the percent cells in both S and G2/M
phases with a corresponding increase in the percent cells
in G1 phase [Fig. 4(B)]. Thus, COMP appears to reduce
the extent of cell proliferation in monolayer cultures by
changing the cell cycle distribution pattern, resulting in
more cells in G1 phase.
Next, the cells infected with either the control virus or the
COMP expressing virus were cultured in a high-density
micromass environment and then treated with or without
BMP-2 (100 ng/ml). The cultures were fixed at Day 10 and
stained with Alcian Blue. As shown in Fig. 5A, BMP-2-
treated cells expressing COMP were stimulated to undergo
chondrogenesis to a higher level than the control cells
treated with BMP-2, as evident by increased Alcian Blue
staining. When the intensity of the stain was quantified by
scanning densitometry, it was found that the COMP ex-
pressing cells showed nearly a twofold increase in the level
of Alcian Blue staining over the control cells [Fig. 5(B)]. That
COMP expression enhanced BMP-2-mediated chondro-
genesis was also evident by measuring metabolic 35SO4
incorporation into extracellular matrix. As seen in Fig. 5C,
by Day 10 of culture the relative level of 35SO4 incorpor-
ation in the COMP-infected cells was higher than that in the
control cells following BMP-2 treatment. This increase in
35SO4 incorporation appears to be a time dependent event,
since the levels of 35SO4 incorporation at early time points(i.e. Days 4 and 7) were nearly equal between the control
and COMP expressing cells.
To assess specific markers of chondrogenesis, the
transcript levels of aggrecan and type II collagen were
measured by RT-PCR. As seen in Fig. 5D, the levels of
both genes were increased by BMP-2 at Day 6. COMP had
only a minor effect on enhancing the expression of these
genes above that of BMP-2. Fig. 5E shows a control at Day
10, where expression of both the A and B forms of collagen
type II are increased in the BMP-2 stimulated micromass
culture. In total, these observations indicate that COMP
may only enhance certain aspects of chondrogenesis, such
as those reflected by Alcian Blue staining and sulfate
incorporation.
IN THE PRESENCE OF BMP-2, COMP EXPRESSION CAUSES AN
INCREASE IN APOPTOSIS AND A LOSS OF CELLS IN THE
MICROMASS CULTURE
Since the data in Fig. 5 indicated that COMP enhanced
some aspects of chondrogenesis (i.e. by sulfate incorpor-
ation and Alcian Blue staining) but only at Day 10 of culture,
later cultures were therefore examined to assess the long-
term effects of COMP. Control and COMP expressing
micromasses, with and without BMP-2 treatment as de-
scribed in Figs. 2 and 5, were examined to Day 16.
Interestingly, we observed that on Days 13 and 16, the
COMP expressing micromass cultures treated with BMP-2
have lost all Alcian Blue staining, while the control culture
treated with BMP-2 retained its staining intensity (shown in
Fig. 6). This indicates that either the cultures had lost a
majority of their sulfated proteoglycan-rich matrix or that the
cultures had a dramatic reduction in the numbers of cells.
Fig. 4. Cells expressing COMP display a slow growth phenotype with increased numbers of cells in the G1 phase of the cell cycle.
C3H10T1/2 cells infected with control and COMP expressing retrovirus, as in Fig. 3, were seeded at 100,000 cells/10 cm plate in monolayer.
At the indicated days, the cells were trypsinized and processed for viable cell counts (by trypan blue exclusion) and flow cytometry was
performed. Shown in (A) are the total viable cell numbers/plate on the indicated days. Shown in (B) are the cell cycle distributions taken at
Day 3 of cell culture. The data show that compared with the control (open circle), COMP expression (solid circle) leads to a slower growth
rate with a correspondingly increased number of cells in G1 phase and fewer cells in S/G2/M phases.
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As a control, the cells not treated with BMP-2 (control and
COMP) do not show any Alcian Blue staining.
To determine if the cell numbers within the COMP
expressing, BMP-2-treated micromass have changed dur-
ing the late time periods, the number of viable cells were
counted, via trypan blue exclusion staining of trypsinized
cells. As seen in Fig. 7A, the cell numbers in all the
cultures increased with time, with the exception of the
COMP expressing cells treated with BMP-2. These cells
demonstrate a noticeable drop in cell numbers by Day
14. The level of protein synthesis in these cultures also
reflects this. As seen in Fig. 7B, the level of protein
synthesis is relatively the same in all the cultures at Day
10, and at Day 16, with the exception of the COMP
expressing cells treated with BMP-2. At Day 16, these
cells show a significant drop in the amount of protein
synthesis. This reduction in protein synthesis correlates
well with the reduced cell numbers in these cultures.
We next assessed whether the drop in cell numbers was
due to an increase in apoptosis. The percent apoptotic cells
in a population can be derived from flow cytometry analy-
sis, which is evident as cells with less than a 2N (or Diploid)
Fig. 5. Retroviral expression of COMP in cultures of BMP-2-treated C3H10T1/2 mesenchymal cells stimulates chondrogenesis. C3H10T1/2
cells infected with either control or COMP expressing retrovirus were cultured in micromass, then treated with or without BMP-2 (100 ng/ml)
as described earlier. (A) Alcian Blue staining. The micromass cultures were fixed on Day 10 and stained with Alcian Blue. The data show that
COMP expressing cells treated with BMP-2 have a higher level of Alcian Blue staining than the control cultures treated with BMP-2. (B)
Quantification of Alcian Blue staining. The micromasses in (A) were scanned digitally and the staining intensity was measured. The levels
were set relative to the control (control set equal to 1). As shown, the staining intensity in the COMP expressing cells treated with BMP-2 is
significantly greater than the control cells treated with BMP-2. The error bars indicate the standard deviation of the mean. (C) Metabolic
sulfate incorporation. The cultures, as in (A), were radiolabeled with 35SO4 (5 µCi/ml final concentration) for a 24-h period ending on Days
4, 7 or 10. 3H-leucine at 1 µCi/ml (final concentration) was also added as a control to standardize for differences in protein levels. The
cultures were washed, fixed and the amount of radiolabel incorporation was determined. The ratios of 35SO4 to 3H-leucine incorporation on
Days 4, 7 and 10 reveal that the COMP expressing cells treated with BMP-2 demonstrate a significantly greater sulfate incorporation on Day
10, compared with the control. Symbols: pBABE alone (open square), pBABE+BMP-2 (open diamond), COMP alone (open circle) and
COMP+BMP-2 (open triangle). (D) RT-PCR analysis. Total RNA was isolated from the control and COMP micromass cultures (with and
without BMP-2 treatment) on Day 6. One microgram of RNA was processed for RT-PCR using primers specific for mouse collagen type II,
collagen, aggrecan and β-actin. The products were electrophoresed on agarose gels stained with ethidium bromide. The stained products
reveal that BMP-2 stimulation leads to increased expression of aggrecan and collagen type II. The primers for type II collagen differentiate
between the ‘A’ and ‘B’ forms of the transcript (the ‘B’ form is cartilage specific). The reaction products, as shown (left side), were
electrophoresed on an agarose gel, which was stained with ethidium bromide. The stained gel shows a higher level of expression of both
collagen type II transcripts in the BMP-2-treated cultures relative to the levels of β-actin mRNA. However, expression of COMP had only a
minor effect on enhancing the expression of these matrix genes. (E) As a control, RNA was isolated from Day 10 micromass cultures (with
and without BMP-2 treatment), and processed for RT-PCR for collagen type II. Shown are the ‘A’ and ‘B’ forms of type II collagen. The ‘B’
form is expressed only in the BMP-2-treated micromass condition.
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DNA content39. As seen in Fig. 7C, there is a dramatic
increase in apoptosis in the COMP expressing cultures
treated with BMP-2 at Day 13. The other culture conditions
show a background level of apoptosis that does not appear
to increase by Day 13. These data indicate that the loss in
cell number in the COMP expressing cells treated with
BMP-2 may be due in part to an increase in apoptosis.
While cell number decreases by over fivefold in the
COMP expressing micromass cultures treated with BMP-2,
we were interested in assessing whether the remaining
cells had been altered in terms of their differentiation
program. RT-PCR was performed on total RNA, using
primers specific for aggrecan, collagen type II and collagen
type X. As seen in Fig. 8A, the COMP expressing cells
Fig. 6. Loss of Alcian Blue staining in long-term micromass cultures of COMP expressing cells treated with BMP-2. C3H10T1/2 cells infected
with either control or COMP expressing retrovirus were plated in micromass cultures, as in Fig. 5, then treated with or without BMP-2
(100 ng/ml). The cultures were fixed and stained with Alcian Blue on the indicated days (4,7,10,13,16). The data show that in the absence
of COMP expression, BMP-2 enhances the level of Alcian Blue staining, peaking on Day 10, and remaining above background to Day 16.
Following COMP expression by retroviral gene transfer and in the presence of BMP-2, Alcian Blue staining was elevated until Day
10. However, the staining level dropped to background on Days 13 and 16 in the COMP expressing-BMP-2-treated cultures.
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treated with BMP-2 retained their expression of aggrecan
and collagen type II. In the cells expressing COMP, but not
treated with BMP-2, the levels of aggrecan were slightly
enhanced over that of the control. These data indicate
that even though there is significant loss of cells in
the ‘COMP+BMP-2’ condition, the remaining cells have
retained their chondrogenic differentiation program, as
reflected by enhanced expression of aggrecan and
collagen type II.
Also assessed by RT-PCR was collagen type X gene
expression. This collagen is normally expressed in
chondrocytes undergoing hypertrophy51–53. As seen in Fig.
8A (left side), collagen type X expression was enhanced in
both the BMP-2 and COMP cultures. These data would
indicate that at this late stage of culture, both BMP-2 and
COMP have a positive effect on the expression levels of
collagen type X. As a control, the right hand portion of Fig.
8A, shows both the A and B forms of collagen type II
Fig. 7. Reduction in cell numbers and protein synthesis but an increase in apoptosis in long-term micromass cultures of COMP expressing
cells treated with BMP-2. C3H10T1/2 cells infected with either control or COMP expressing retrovirus were cultured in micromass, then
treated with or without BMP-2 (100 ng/ml). (A) Viable cell counts. The cultures were processed for viable cell counts on Days 0 and 14. The
numbers of viable cells are shown, plus or minus the standard deviation from the mean. The data indicate that the COMP expressing cells
treated with BMP-2 show a significant decrease in cell numbers on Day 14 compared with the other conditions. (B) 3H-leucine incorporation.
3H-leucine was added to the micromass cultures for a 24-h period ending at Day 10 or 16 (1 µCi/ml final concentration). The counts per
minute (CPM) of 3H-leucine incorporation on Day 10 (left side) and Day 16 (right side) are shown, plus or minus the standard deviation of
the mean. The data show that the level of leucine incorporation between the different conditions is roughly equal on Day 10, while on Day
16 the COMP expressing cells treated with BMP-2 show a significant decrease in incorporation. (C) Apoptosis. The cultures on Days 10 and
13 were processed for flow cytometry. The percent apoptotic cells was determined as those cells having less than 2N DNA content and is
shown plus or minus the standard deviation of the mean. The data show that the level of apoptosis is roughly equal on Day 10 while on Day
13, the COMP expressing cells treated with BMP-2 show a significant increase in the level of apoptosis.
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elevated at a Day 10 time point in the BMP-2-treated
micromass cultures.
As an additional test to determine if the chondrogenic
phenotype of the COMP expressing cells treated with
BMP-2 was retained, the cells were assessed for incor-
poration of 35SO4. As seen in Fig. 8B, the ratio of 35SO4 to
3H-leucine incorporation (i.e. 35SO4 incorporation normal-
ized to equal levels of protein synthesis) is higher in the
BMP-2-treated cultures than in the control and COMP
expressing cultures at the Day 16 time point. That this ratio
is elevated for the COMP expressing cells treated with
BMP-2, indicates that the remaining viable cells in the
micromass environment are indeed undergoing an in-
creased level of chondrogenesis, and is consistent with the
RT-PCR data presented in Fig. 8A.
Discussion
A central question surrounding cartilage development
and function is the role that specific extracellular matrix
proteins play in this process. Towards answering this ques-
tion, we have explored the role of COMP in mesenchymal
chondrogenesis. In this study, we have used an in vitro
system consisting of a murine mesenchymal cell line,
C3H10T1/2 cells, which are multipotential and capable of
differentiating along chondrogenic lines in a micromass
culture system, following treatment with BMP-220–22,24.
From the data presented earlier, it appears that COMP has
multiple effects on these mesenchymal cells in this in vitro
system. While it affects cell proliferation and enhances
chondrogenic gene expression, it also induces cell death in
the presence of BMP-2.
The first function of COMP, apparent from the studies
here, is that it affects the level of cell proliferation. It seems
that COMP expression slows the rate of growth, without
any obvious detrimental effects on cell viability or mor-
phology. This reduction in growth rate corresponds to an
increase in the percent of cells in G1 phase and a decrease
in the percent of cells in S, G2 and M phases. Since the
primary effect of COMP appears to be a partial G1 arrest,
this would suggest the involvement of particular cell cycle
regulators, namely members of the retinoblastoma gene
family as well as the cyclin dependent kinase inhibitors, on
COMP-mediated inhibition of growth. These proteins to-
gether regulate transit through the G1 checkpoint and are
thought to be primarily responsible for induction of G1
arrest40,41. An activation of any of these cell cycle regu-
lators by COMP may not be unexpected since it has been
demonstrated, for example, that fibrillar collagen type I can
inhibit proliferation of arterial smooth muscle cells through
the upregulation of the p21/p27 CDIs42. While the effect of
collagen type I on smooth muscle appears to be mediated
through the integrins, it remains to be seen if COMP
accomplishes this inhibition through a similar mechanism.
From the data here, it appears that COMP also has an
effect on enhancing some aspects of chondrogenesis. This
enhancement occurs during the middle phase of the micro-
mass culture period (i.e. by Day 10) and only in the
presence of BMP-2 treatment. This suggests a number of
features for COMP function. One is that COMP mediates a
signaling pathway in the cell and that this pathway con-
verges with that of BMP-2 signaling. Since COMP is part of
the thrombospondin family, which binds the CD36 and
CD47 receptors43,44, the effects of COMP may be medi-
ated through a thrombospondin-type receptor signaling
mechanism. In addition, given that COMP contains an RGD
sequence, it is possible that COMP mediates signaling
through an integrin. The other important feature of the
COMP enhancement of BMP-2 induced chondrogenesis is
that BMP-2 and COMP function in a synergistic way,
suggesting that the signaling pathway of COMP may con-
verge on that of BMP-2. As mentioned earlier, enhance-
ment of chondrogenesis by COMP, in the presence of
Fig. 8. Markers of chondrogenesis and sulfate incorporation are
maintained in long-term micromass cultures of COMP expressing
cells treated with BMP-2. C3H10T1/2 cells infected with either
control or COMP expressing retrovirus were cultured in micro-
mass, and then treated with or without BMP-2 (100 ng/ml). (A)
RT-PCR analysis. (Left side) Total RNA was isolated from the
control and COMP expressing micromass cultures (with and with-
out BMP-2 treatment) on Day 14. One microgram of RNA was
processed for RT-PCR using primers specific for mouse collagen
type II, aggrecan, collagen X and β-actin. The primers for type II
collagen differentiate between the ‘A’ and ‘B’ forms of the transcript
(the ‘B’ form is cartilage specific). The products were electro-
phoresed on agarose gels, which were subsequently stained with
ethidium bromide. The stained products are shown. The data show
that in the cells remaining in the COMP+BMP-2 conditions, expres-
sion of aggrecan as well as collagen type II are elevated compared
with the controls. (Right side) As a control, RNA was isolated from
Day 10 micromass cultures (with and without BMP-2 treatment),
and processed for RT-PCR for collagen type II. Shown are the ‘A’
and ‘B’ forms of type II collagen. The ‘B’ form is expressed only in
the BMP-2-treated micromass condition. (B) Metabolic sulfate
incorporation. 35SO4 was added to the culture (5 µCi/ml final
concentration) for a 24-h period ending at Day 16 (3H-leucine at
1 µCi/ml final concentration was also added as a control to
standardize for differences in protein levels). The ratios of 35SO4 to
3H-leucine incorporation on Day 16 are shown. The error bars
represent the standard deviation of the mean. The data reveal that
the COMP expressing cells treated with BMP-2 demonstrate
a significantly enhanced incorporation of sulfate relative to the
negative controls.
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BMP-2, appears to require about 7–10 days of culture to be
evident. This temporal requirement is of potential signifi-
cance. From the data presented here and elsewhere20,
BMP-2 acting alone as a differentiation-inducing signal on
C3H10T1/2 micromass cultures requires a 3–5 day treat-
ment period during the initial phase of culture. Since the
effect of COMP on chondrogenesis requires 10 days,
COMP signaling is likely to act downstream of BMP-2
signaling.
An interesting outcome of the studies presented here
was that ectopic expression of COMP had a pro-apoptotic
effect on the cell cultures. The data showed that COMP
increases the extent of apoptosis late in the culture period
(i.e. after Day 10), but only in the presence of BMP-2. This
corresponded to a loss of cells in the micromass culture
along with a loss of Alcian Blue staining intensity. At this
time we do not know if this is a direct or indirect effect of
COMP, which remains to be determined. Surprisingly, the
remaining cells in the micromass retained their differenti-
ated state, as reflected by elevated aggrecan and collagen
type II gene expression and sulfate incorporation. Thus,
BMP-2 and COMP signaling have a rather unique syner-
gistic effect late in the culture period, corresponding to a
fully chondrocytic cellular phenotype. That this effect of
COMP only occurs in the presence of BMP-2, suggests that
an apoptotic mechanism is induced by the convergence of
COMP and BMP-2 signaling.
A number of possibilities exist for these cells to be
induced to undergo apoptosis by BMP-2 treatment and
ectopic expression of COMP. The first is that the maturation
pathway of chondrocytes during endochondral ossification
is well known to result in induction of apoptosis54. Although
we do not have solid morphological evidence that BMP-2-
treated C3H10T1/2 micromass cultures are undergoing
hypertrophy (i.e. the cells are enlarged), we surprisingly do
see induction of collagen type X by both COMP and
BMP-2. Collagen type X is well known as a very specific
marker of hypertrophic chondrocytes51–53. That collagen
type X is induced in these cells is in line with our finding that
COMP is expressed at high levels in regions undergoing
both hypertrophy and mineralization during development.
This can be seen in Fig. 1, where the high level of COMP
expression in the digits and tail vertebra overlaps with the
pink Mallory’s stain, the latter indicating formation of min-
eralized bone in the region of chondrocyte hypertrophy. It is
therefore possible that COMP and BMP-2 aid in the induc-
tion of apoptosis through a chondrocyte maturation path-
way. In this regard it is known that BMP signaling (in
particular BMP-6, 2 and 7) plays a very important role in the
induction of hypertrophy54,55. Thus, it may be that during
development, or during fracture repair in the adult, BMP
and COMP combine to facilitate chondrocyte maturation
through hypertrophy and apoptosis, as part of endochon-
dral ossification. However, additional work will be needed to
determine if this is indeed the case.
An additional possibility for the induction of apoptosis by
COMP and BMP-2 involves interdigital apoptosis. Given
that the BMP-2 effect on enhancement of chondrogenesis
is an early event, the cells that respond to COMP appear
committed to the chondrocytic phenotype. Along these
lines, the patterning of the cartilaginous model requires
spatio-temporal specific apoptosis that can be observed in
the interdigital zones of the developing limb45. As shown in
Fig. 1, COMP expression is high in the digital zones of the
limb (i.e. in the footpad), immediately adjacent to the areas
that are undergoing cell death. It has been previously
shown that BMP-2, while chondrogenic for the undifferen-
tiated mesenchyme, is responsible for apoptosis in the
interdigital zones46–49. By extrapolating to the in vitro
micromass cultures that ectopically express COMP and are
treated with BMP-2, we would expect enhanced apoptosis
in a significant portion of the cells, while the remaining
viable cells would be chondrocytic. We have observed here
that early chondrogenesis is enhanced, yet later in culture
we see an induction of apoptosis.
In conclusion, we have identified a novel role for COMP
in chondrogenesis. COMP enhances BMP-2-mediated
chondrogenesis during the middle phase of culture and
then leads to enhanced apoptosis late in culture. Use of this
in vitro micromass culture system should enable us to
further probe the mechanisms responsible for these effects
of COMP and their relation to chondrocyte differentiation
and cartilage biology. These results are especially pertinent
given the recent findings that COMP null mice demonstrate
no detectable skeletal defects, including effects on carti-
lage50. It therefore may be that the in vitro mechanism used
here, in conjunction with a gain-of-function approach of
retroviral gene transfer, may be optimal for assessing the
exact role of COMP in chondrogenesis.
Acknowledgements
We thank the Kimmel Cancer Institute Flow Cytometry
Center, Thomas Jefferson University, for their help in cell
cycle/apoptosis analysis.
References
1. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D,
Paulsson M, Rosa-Pimente E, et al. Cartilage matrix
proteins. An acidic oligomeric protein (COMP) de-
tected only in cartilage. J Biol Chem 1992;
267:6132–6.
2. Oldberg A, Antonsson P, Lindblom K, Heinegard D.
COMP (cartilage oligomeric matrix protein) is struc-
turally related to the thrombospondins. J Biol Chem
1992;267:22346–50.
3. Newton G, Weremowicz S, Morton CC, Copeland NG,
Gilbert DJ, Jenkins NA, et al. Characterization of
human and mouse cartilage oligomeric matrix
protein. Genomics 1994;24:435–9.
4. Morgelin M, Heinegard D, Engel J, Paulsson M. Elec-
tron microscopy of native cartilage oligomeric matrix
protein purified from Swarm rat chondrosarcoma
reveals a five-armed structure. J Biol Chem 1992;
267:6137–41.
5. Efimov VP, Lustig A, Engel J. The thrombospondin-like
chains of cartilage oligomeric matrix protein are as-
sembled by a five-stranded α-helical bundle between
residues 20 and 83. FEBS Lett 1994;341:54–8.
6. Malashkevich VN, Kammerer RA, Efimov VP,
Schulthess T, Engel J. The crystal structure of a
five-stranded coiled coil in COMP: a prototype ion
channel? Science 1996;274:761–5.
7. DiCesare PE, Morgelin M, Carlson CS, Pasumarti S,
Paulsson M. Cartilage oligomeric matrix protein: iso-
lation and characterization from human articular
cartilage. J Orthop Res 1995;13:422–8.
8. DiCesare PE, Hauser N, Lehman D, Pasumarti S,
Paulsson M. Cartilage oligomeric matrix protein
(COMP) is an abundant component of tendon. FEBS
Lett 1994;354:237–40.
452 J. Kipnes et al.: Effect of COMP on chondrogenesis
9. Murphy JM, Heinegard D, McIntosh A, Sterchi D, Barry
FP. Distribution of cartilage molecules in the devel-
oping mouse joint. Matrix Biol 1999;18:487–97.
10. Chen H, Herndon ME, Goldring MB, Hecht JT, Lawler
J. Function of cartilage oligomeric matrix protein.
48th Annual Meeting of the Orthopaedic Research
Society, February 10–13, 2002, Dallas, TX.
11. Briggs MD, Hoffman SMG, King LM, Olsen AS,
Mohrenweiser H, Leroy JG, et al. Pseudoachondro-
plasia and multiple epiphyseal dysplasia due to
mutations in the cartilage oligomeric matrix protein
gene. Nat Genet 1995;10:330–6.
12. Hecht JT, Nelson LD, Crowder E, Wang Y, Elder FB,
Harrison WR, et al. Mutations in exon 17B of cartilage
oligomeric matrix protein (COMP) cause pseudo-
achondroplasia. Nat Genet 1995;10:325–9.
13. Briggs MD, Mortier GR, Cole GW, King LM, Golik SS,
Bonaventure J, et al. Diverse mutations in the gene
for cartilage oligomeric matrix protein in the
pseudoachondroplasia-multiple epiphyseal dysplasia
disease spectrum. Am J Hum Genet 1998;62:311–9.
14. Deere M, Sanford T, Ferguson HL, Daniels K, Hecht
JT. Identification of twelve mutations in cartilage
oligomeric matrix protein (COMP) in patients with
pseudoachondroplasia. Am J Med Genet 1998;
80:510–3.
15. Delot E, King ML, Briggs MD, Wilcox WR, Cohn DH.
Trinucleotide expansion mutations in the cartilage
oligomeric matrix protein (COMP) gene. Hum Mol
Genet 1999;8:123–8.
16. Ikegawa S, Ohashi H, Nishimura G, Kim KC, Sannohe
A, Kimizuka M, et al. Novel and recurrent COMP
(cartilage oligomeric matrix protein) mutations in
pseudoachondroplasia and multiple epiphyseal
dysplasia. Hum Genet 1998;103:633–8.
17. Loughlin J, Irven C, Mustafa Z, Briggs MD, Carr A,
Lynch SA, et al. Identification of five novel mutations
in cartilage oligomeric matrix protein gene in pseudo-
achondroplasia and multiple epiphyseal dysplasia.
Hum Mutat Suppl 1998;1:S10–8.
18. Maddox BK, Keene DR, Sakai LY, Charbonneau NL,
Morris NP, Ridgway C, et al. The fate of cartilage
oligomeric matrix protein is determined by the cell
type in the case of a novel mutation in pseudo-
achondroplasia. J Biol Chem 1997;272:30993–7.
19. Susic S, McGrory J, Ahier J, Cole WG. Multiple epie-
physeal dysplasia and pseudoachondroplasia due to
novel mutations in the calmodulin-like repeats of
cartilage oligomeric matrix protein. Clin Genet 1997;
51:219–24.
20. Denker AE, Haas AR, Nicoll SB, Tuan RS. Chondro-
genic differentiation of murine C3H10T1/2 multi-
potential mesenchymal cells: II. Stimulation by bone
morphogenetic protein-2 in high density micromass
cultures. Differentiation 1999;64:67–76.
21. Haas AR, Tuan RS. Chondrogenic differentiation of
murine C3H10T1/2 multipotential mesenchymal
cells: II. Stimulation by bone morphogenetic protein-2
requires modulation of N-cadherin expression and
function. Differentiation 1999;64:77–89.
22. Carlberg AL, Pucci B, Rallapalli R, Tuan RS, Hall DJ.
Efficient chondrogenic differentiation of mesenchy-
mal cells in micromass culture by retroviral gene
transfer of BMP-2. Differentiation 2001;67:128–38.
23. Fischer L, Boland G, Tuan RS. Wnt signaling during
BMP-2 stimulation of mesenchymal chondrogenesis.
J Cell Biochem 2002;84:816–31.
24. Ahrens PB, Solursh M, Reiters R. Stage-related
capacity for limb chondrogenesis in cell culture. Dev
Biol 1977;60:69–82.
25. Denker AE, Nicoll SB, Tuan RS. Formation of
cartilage-like spheroids by micromass cultures of
murine C3H10T1/2 cells upon treatment with
transforming growth factor-β1. Differentiation 1995;
59:25–34.
26. Jordan-Sciutto KL, Logan TJ, Norton PA, Derfoul A,
Dodge GR, Hall DJ. Reduction in fibronectin expres-
sion and alteration in cell morphology are coincident
in NIH3T3 cells expressing a mutant E2F1 transcrip-
tion factor. Exp Cell Res 1997;236:527–36.
27. Wawersik S, Epstein JA. Gene expression analysis by
in situ hybridization. In: Tuan RS, Lo CW, Eds.
Methods in Molecular Biology Developmental Biology
Protocols, Volume III: Humana Press 2000;Volume
137:87–96.
28. Kipnes JR, Xu L, Han F, Rallapalli R, Knowlton RG,
Jimenez S, et al. Molecular cloning and expression
patterns of mouse cartilage oligomeric matrix protein
gene. Osteoarthritis Cartilage 2000;8:236–9.
29. Taylor SM, Jones PA. Multiple new phenotypes in-
duced in 10T1/2 and 3T3 cells treated with
5-azacytidine. Cell 1979;17:771–9.
30. Katagiri T, Yamaguchi A, Ideda T, Yoshiki S, Wozney
JM, Rosen V, et al. The non-osteogenic mouse
pluripotent cell line, C3H10T1/2 is induced to differ-
entiate into osteoblastic cells by recombinant human
bone morphogenetic protein-2. Biochem Biophys
Res Commun 1990;172:295–9.
31. Izzo MW, Pucci B, Tuan RS, Hall DJ. Identification of
genes whose expression patterns are both up and
down regulated following induction of chondrogen-
esis in vitro. Osteoarthritis Cartilage 2002;10:23–33.
32. Wang EA, Israel DI, Kelly S, Luxenberg DP. Bone
morphogenetic protein-2 causes commitment and
differentiation in C3H10TG1/2 and 3T3 cells. Growth
Factors 1993;9:57–71.
33. McLeod MJ. Differential staining of cartilage and bone
in whole mouse fetuses by alcian blue and alizarin
red S. Teratology 1980;22:299–301.
34. Sandberg MM, Hirvonen HE, Elima KJM, Vuorio I.
Co-expression of collagen II and XI and alternative
splicing of exon 2 of collagen II in several developing
human tissues. Biochem J 1993;294:595–602.
35. Sandell LJ, Nalin AM, Reife RA. Alternative splice form
of type II procollagen mRNA (IIA) is predominant in
skeletal precursors and non-cartilaginous tissues
during early mouse development. Dev Dyn 1994;
199:129–40.
36. Hecht JT, Montufar-Solis D, Decker G, Lawler J,
Daniels K, Duke PJ. Retention of cartilage oligomeric
matrix protein (COMP) and cell death in redifferenti-
ated pseudoachondroplasia chondrocytes. Matrix
Biol 1998;1:625–33.
37. Delot E, Brodie SG, King LM, Wilcox WR, Cohn DH.
Physiological and pathological secretion of cartilage
oligomeric matrix protein by cells in culture. J Biol
Chem 1998;273:26692–7.
38. Rimoin DL, Rasmussen IM, Briggs MD, Roughley PJ,
Gruber HE, Warman ML, et al. A large family with
features of pseudoachondroplasia and multiple epi-
physeal dysplasia: exclusion of seven candidate
gene loci that encode proteins of the cartilage extra-
cellular matrix. Hum Genet 1994;93:236–42.
Osteoarthritis and Cartilage Vol. 11, No. 6 453
39. Logan TJ, Evans DL, Mercer WE, Bjornsti MA, Hall DJ.
Cell lines expressing a mutant form of the E2F1
transcription factor have a prolonged S phase and
show increased sensitivity to the S phase specific
toxin camptothecin. Cancer Res 1995;55:2883–91.
40. Hunter T, Pines J. Cyclins and cancer II: cyclin D and
cdk inhibitors come of age. Cell 1994;79:573–82.
41. Sherr CJ. Cancer cell cycles. Science 1996;
274:1672–7.
42. Koyama H, Raines EW, Bornfeldt KE, Roberts JM,
Ross R. Fibrillar collagen inhibits arterial smooth
muscle proliferation through regulation of cdk2
inhibitors. Cell 1996;87:1069–76.
43. Bornstein P, Armstrong LC, Hankenson KD,
Kyriakides TR, Yang Z. Thrombospondin 2, a matri-
cellular protein with diverse functions. Matrix Biol
2000;19:557–68.
44. Lawler J. The functions of thrombospondins-1 and -2.
Curr Opin Cell Biol 2000;1:634–40.
45. Capdevila J, Izpisua-Belmonte JC. Patterning mecha-
nisms controlling vertebrate limb development. Annu
Rev Cell Dev Biol 2001;17:87–132.
46. Zou H, Niswander L. Requirement of BMP signaling in
interdigital apoptosis and scale formation. Science
1996;272:738–41.
47. Zou H, Wieser R, Massague J, Niswander L. Distinct
roles of type I bone morphogenetic protein receptors
in the formation and differentiation of cartilage.
Genes Dev 1997;11:2191–203.
48. Macias D, Ganan Y, Sampath TK, Piedra ME, Ros MA,
Hurle JM. Role of BMP-2 and OP-1 (BMP-7) in
programmed cell death and skeletatogenesis during
chick limb development. Development 1997;
124:1109–17.
49. Yokouchi Y, Sakiyama J, Kameda T, Iba H, Suzuki A,
Ueno N, et al. BMP-2/-4 mediate programmed cell
death in chicken limb buds. Development 1996;
122:3725–34.
50. Svensson L, Aszodi A, Heinegard D, Hunziker EB,
Reinholt FP, Fassler R, et al. Cartilage oligo-
meric matrix protein deficient mice have normal
skeletal development. Mol Cell Biol 2002;22:
4366–71.
51. Schmid TM, Linsenmayer TF. Immunohistochemical
localization of short chain cartilage collagen (type X)
I avian tissues. J Cell Biol 1985;100:598–605.
52. Oshima O, Leboy PS, Mcdonald SA, Tuan RS, Shapiro
IM. Developmental expression of genes in chick
growth cartilage detected by in situ hybridization.
Calcif Tissue Int 1989;45:182–92.
53. Gerstenfeld LC, Landis WJ. Gene expression and
extracellular matrix ultrastructure of a mineralizing
chondrocyte cell culture system. J Cell Biol 1991;
112:501–13.
54. Volk SW, Leboy PS. Regulating the regulators of
chondrocyte hypertrophy. J Bone Miner Res 1999;
14:483–6.
55. Grimsrud CD, Romano PR, D’Souza M, Puzas JE,
Reynolds PR, Rosier RN, et al. BMP-6 is an
autocrine stimulator for chondrocyte differentiation. J
Bone Miner Res 1999;14:475–82.
454 J. Kipnes et al.: Effect of COMP on chondrogenesis
